BioSpace News Archive

James F. Donohue, MD, Professor of Medicine, Pulmonary Diseases and Critical Care Medicine at the University of North Carolina at Chapel Hill, presented new data from the completed three-month Phase III studies.

IntraFuse received FDA approval for its FlexThread Fibula Pin System which provides percutaneous fixation of distal fibula fractures.

Veracyte announced that data from a prospective clinical utility study show that use of the company’s Percepta Bronchial Genomic Classifier reduces invasive procedures by greater than 50 percent in lung cancer screening and diagnosis.

The collaboration will provide physicians and patients in the region with enhanced and streamlined access to a full range of laboratory testing solutions.

The company will use the funding to further develop its lead imaging compound, OTL38, for use in detecting multiple cancers.

Seattle Genetics today announced that 18 abstracts featuring data from the broad ADCETRIS (brentuximab vedotin) development program have been accepted for presentation.

The oral presentations will highlight safety and efficacy data for a completed phase 2 study of the company’s lead clinical asset, NiCord, as a single cord blood graft, and proof-of-concept data for the advancement of natural killer cells (NK cells) as an immunotherapeutic modality for patients with cancer.

As part of the collaboration, LabCorp has also made an equity investment into MC10.

Alexion Pharmaceuticals announced today that researchers will present new data from two Phase 1/2 clinical studies of ALXN1210.

Intellijoint’s milestone supports Intellijoint Surgical’s mission of making intellijoint HIP accessible to every surgeon and every patient.